Author: admin

DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Gastroenteropancreatic Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Gastroenteropancreatic Neuroendocrine Tumor Market Report:

https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market

Some of the key facts of the Gastroenteropancreatic Neuroendocrine Tumor Market Report:

• The Gastroenteropancreatic Neuroendocrine Tumor market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

• According to the Camurus AB’s 2026 presentation, results from the Phase III (SORENTO) trial are expected to be presented in 2026.

• In November 2025, ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug Application (NDA) for n.c.a. 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide). This proprietary, synthetic, targeted radiotherapeutic investigational agent is being developed by ITM for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The FDA has established a Prescription Drug User Fee Act (PDUFA) target action date of August 28, 2026.

• In March 2025, US FDA approved cabozantinib (CABOMETYX, RayzeBio, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).

• Radioligand therapies and targeted agents are expected to remain key drivers of market expansion.

• Emerging pipeline candidates focusing on receptor targeting, angiogenesis, and combination approaches such as surufatinib, and 177Lu-edotreotide are anticipated to increase competition and shape future treatment strategies.

• The US contributed to the highest incident cases of NETs. The total incident cases of NETs in the United States in 2025 were 31,000.

• According to the secondary search, net project, the incidence of malignant GEP-NET during 2000–2007 was 1.7 per 100,000 population per year in Europe, corresponding to an estimated 26,000 new cases.

• As per the secondary sesrch, the annual incidence of the disease was 6.47 cases per 100,000 population, with an adjusted prevalence of 0.052%. The mean age at diagnosis was 58 ± 15 years, and the gender distribution was nearly equal, with 51% men and 49% women in Spain.

• Surgical resection of the primary tumor was performed in 66% of patients. Histopathological grading showed that most tumors were well differentiated, with 73% classified as Grade 1 (G1), 22% as Grade 2 (G2), and 5% as Grade 3 (G3).

• The most common primary tumor site was the pancreas (52%), followed by the jejunum–ileum (23%). At the time of diagnosis, 24% of patients presented with distant metastases, most frequently involving the liver (44%), peritoneum (25%), or multiple organs (22%). The majority of tumors were sporadic and non-functional.

• Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others

• Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: SOMATULINE DEPOT, ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others

• The Gastroenteropancreatic Neuroendocrine Tumor epidemiology based on gender analyzed that the incidence of functional GEP-NET is more than that of nonfunctional GEP-NET in the United States

• The Gastroenteropancreatic Neuroendocrine Tumor market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroenteropancreatic Neuroendocrine Tumor pipeline products will significantly revolutionize the Gastroenteropancreatic Neuroendocrine Tumor market dynamics.

Gastroenteropancreatic Neuroendocrine Tumor Overview

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) are a diverse group of tumors that arise from neuroendocrine cells in the gastrointestinal (GI) tract and pancreas. These cells have both endocrine and neural characteristics and are responsible for producing hormones that regulate various physiological functions.

To Know in detail about the Gastroenteropancreatic Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GEP-NETs Market Forecast

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology

The Gastroenteropancreatic Neuroendocrine Tumor epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Segmentation:

The Gastroenteropancreatic Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of GEP-NET in the 7MM

• Grade-Specific Cases of GEP-NET in the 7MM

• Tumor site-specific Cases of GEP-NET in the 7MM

• Stage-specific Cases of GEP-NET in the 7MM

• Symptom-specific Cases of GEP-NET in the 7MM

Download the report to understand which factors are driving GEP-NETs epidemiology trends @ Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Forecast

Gastroenteropancreatic Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroenteropancreatic Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Gastroenteropancreatic Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroenteropancreatic Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroenteropancreatic Neuroendocrine Tumor Therapies and Key Companies

• LUTATHERA (lutetium Lu 177 DOTATATE): Novartis

• ITM-11 (n.c.a. 177Lu-edotreotide): ITM Isotope Technologies Munich

• SOMATULINE DEPOT: Ipsen Biopharmaceuticals

• ITM-11: ITM Isotope Technologies Munich

• CAM2029: Camurus

• RYZ101: RayzeBio

• Lanreotide: Merck Sharp & Dohme

• arginine/lysine: Advanced Accelerator

• Temozolomide (TMZ): Ipsen

• Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine

• RYZ101: RayzeBio, Inc.

• CAM2029: Camurus AB

• Everolimus: Novartis

• PEN-221: Tarveda Therapeutics

• Lutathera: Progenics Pharmaceuticals

• Ibrutinib: Pharmacyclics

Discover more about therapies set to grab major GEP-NETs market share @ Gastroenteropancreatic Neuroendocrine Tumor Treatment Market

Gastroenteropancreatic Neuroendocrine Tumor Market Strengths

• GEP-NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes.

• Treatment of GEP-NETs involves a multidisciplinary team of specialists, including oncologists, surgeons, and endocrinologists, which enhances the overall management of the disease.

Gastroenteropancreatic Neuroendocrine Tumor Market Opportunities

• Continued research and development in targeted therapies, such as somatostatin analogs and molecular inhibitors, provide opportunities for more effective and personalized treatment approaches.

• Participation in clinical trials can lead to the discovery of new treatment modalities and contribute to the improvement of patient outcomes.

Scope of the Gastroenteropancreatic Neuroendocrine Tumor Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others

• Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: SOMATULINE DEPOT, ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others

• Gastroenteropancreatic Neuroendocrine Tumor Therapeutic Assessment: Gastroenteropancreatic Neuroendocrine Tumor current marketed and Gastroenteropancreatic Neuroendocrine Tumor emerging therapies

• Gastroenteropancreatic Neuroendocrine Tumor Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumor market drivers and Gastroenteropancreatic Neuroendocrine Tumor market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs, KOL’s views, Analyst’s views, Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement

To know more about GEP-NETs companies working in the treatment market, visit @ Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials and Therapeutic Assessment

Table of Contents

1. Gastroenteropancreatic Neuroendocrine Tumor Market Report Introduction

2. Executive Summary for Gastroenteropancreatic Neuroendocrine Tumor

3. SWOT analysis of Gastroenteropancreatic Neuroendocrine Tumor

4. Gastroenteropancreatic Neuroendocrine Tumor Patient Share (%) Overview at a Glance

5. Gastroenteropancreatic Neuroendocrine Tumor Market Overview at a Glance

6. Gastroenteropancreatic Neuroendocrine Tumor Disease Background and Overview

7. Gastroenteropancreatic Neuroendocrine Tumor Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroenteropancreatic Neuroendocrine Tumor

9. Gastroenteropancreatic Neuroendocrine Tumor Current Treatment and Medical Practices

10. Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs

11. Gastroenteropancreatic Neuroendocrine Tumor Emerging Therapies

12. Gastroenteropancreatic Neuroendocrine Tumor Market Outlook

13. Country-Wise Gastroenteropancreatic Neuroendocrine Tumor Market Analysis (2022–2036)

14. Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement of Therapies

15. Gastroenteropancreatic Neuroendocrine Tumor Market Drivers

16. Gastroenteropancreatic Neuroendocrine Tumor Market Barriers

17. Gastroenteropancreatic Neuroendocrine Tumor Appendix

18. Gastroenteropancreatic Neuroendocrine Tumor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroenteropancreatic Neuroendocrine Tumor Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator

DelveInsight’s “Hereditary Transthyretin Amyloidosis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Hereditary Transthyretin Amyloidosis, historical and forecasted epidemiology as well as the Hereditary Transthyretin Amyloidosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get a Free sample for the Hereditary Transthyretin Amyloidosis Market Report:

https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market

Some of the key facts of the Hereditary Transthyretin Amyloidosis Market Report:

• The hereditary transthyretin amyloidosis (hATTR) market size is estimated to attain a value of nearly USD 3,000 million in 2025 and is anticipated to register a strong CAGR of 11% throughout the forecast period from 2026 to 2036.

• According to estimates, the United States represented the largest share of the hATTR market in 2025, with a market size of nearly USD 2,000 million.

• In March 2026, Intellia Therapeutics presentation, the Nex-Z ATTR program outlines a planned resumption of patient enrollment in the Phase III MAGNITUDE trial in ATTR-CM, resumption of patient enrollment in the Phase III MAGNITUDE-2 trial in ATTRv-PN, and expected completion of enrollment in MAGNITUDE-2 in the second half of 2026.

• In February 2026, according to the Q4 and Full Year 2025 financial results of Alnylam Pharmaceuticals, the company plans to launch Nucresiran, a next-generation RNA silencer for Transthyretin Amyloidosis, with a potential launch timeline of 2028 for polyneuropathy and 2030 for cardiomyopathy indications.

• As per the Ionis Pharmaceuticals Q4 2025 presentation, eplontersen is highlighted as a key asset, with an NDA submission expected in 2026 and a potential launch anticipated in 2027 for hATTR-CM.

• In September 2025, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a clinical-stage gene editing company advancing CRISPR-based therapies, announced longer-term follow-up data from its ongoing Phase 1 study of nexiguran ziclumeran (nex-z) for treating hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). The findings were presented in an oral session on September 25 at the 5th International ATTR Amyloidosis Annual Meeting for Patients and Doctors in Baveno, Italy. The results were also published in the New England Journal of Medicine, and the presentation is available on the Scientific Publications & Presentations section of intelliatx.com.

• In August 2025, Pfizer announced that it would discontinue VYNDAQEL (tafamidis meglumine) in the United States effective December 31, 2025, while confirming that VYNDAMAX (tafamidis) would continue to remain available for all eligible patients with a prescription.

• In August 2025, Prothena Corporation announced that Novo Nordisk, during its Q2 2025 update, confirmed plans to advance coramitug, a potential first-in-class amyloid-clearing antibody, into a Phase III trial for ATTR amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Originally developed by Prothena, coramitug was acquired by Novo Nordisk in July 2021.

• In June 2025, Alnylam Pharmaceuticals announced that the European Commission (EC) has approved an expanded indication for AMVUTTRA (vutrisiran), an orphan RNAi therapy, for treating wild-type or hereditary transthyretin amyloidosis (ATTR-CM) in adult patients with cardiomyopathy.

• In March 2025, Alnylam Pharmaceuticals announced that the US FDA approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hATTR-CM in adults to reduce cardiovascular mortality, cardiovascular hospitalisations, and urgent heart failure visits. The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hATTR-PN in adults.

• As per DelveInsight’s analysis, the US accounted for nearly 65% of the total diagnosed prevalent cases of hATTR in the 7MM in 2025, which is expected to increase further by 2036.

• The secondary analysis indicates that hATTR generally affects both males and females equally, with no clear gender predominance. However, a possible parent-of-origin effect is suggested, as maternal inheritance may increase disease risk. In contrast, late-onset familial cases tend to show a higher prevalence among males.

• A Japan-based study revealed that late-onset and nonendemic cases of hATTR are more common than previously recognised. Disease severity by ambulatory status showed 59% in stage 1, 19% in stage 2, and 14% in stage 3.

• In 2025, France recorded the highest diagnosed prevalence of hATTR among other EU4 countries and the United Kingdom.

• In the USA, the highest proportion of hATTR cases is seen in Familial Amyloid Polyneuropathy (FAP) at 45%, followed by mixed hATTR, while the lowest proportion is observed in Familial Amyloid Cardiomyopathy (FAC).

• In the USA, the New York Heart Association (NYHA) classification of FAC shows that the majority of patients fall under Class II (60%), followed by Class III, while the lowest proportion is seen in Class IV.

• Key Hereditary Transthyretin Amyloidosis Companies: Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia Therapeutics, Regeneron, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others

• Key Hereditary Transthyretin Amyloidosis Therapies: Vutrisiran (AMVUTTRA), Eplontersen (WAINUA/WAINZUA), Vutrisiran (AMVUTTRA), Patisiran (ONPATTRO), Inotersen (TEGSEDI), Tafamidis (VYNDAMAX), Nexiguran ziclumeran (nex-z), Nucresiran, WAINUA (eplontersen), ONPATTRO (patisiran), TEGSEDI (inotersen), Nexiguran Ziclumeran, ALXN2220 (formerly NI006), Coramitug, Eplontersen, Acoramidis (AG 10), CRX-1008 (Tolcapone; SOM0226), PRX004, NTLA-2001, and others

• The Hereditary Transthyretin Amyloidosis epidemiology based on gender analyzed that FAP is the most affected type-specific hATTR in the US

• The Hereditary Transthyretin Amyloidosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Transthyretin Amyloidosis pipeline products will significantly revolutionize the Hereditary Transthyretin Amyloidosis market dynamics.

Hereditary Transthyretin Amyloidosis Overview

Hereditary Transthyretin Amyloidosis (hATTR), also known as transthyretin amyloidosis or ATTRv amyloidosis, is a rare, inherited disorder characterized by the accumulation of abnormal deposits of a protein called transthyretin (TTR) in various tissues and organs throughout the body.

To Know in detail about the Hereditary Transthyretin Amyloidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Transthyretin Amyloidosis Market Forecast

Hereditary Transthyretin Amyloidosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hereditary Transthyretin Amyloidosis Epidemiology Segmentation:

The Hereditary Transthyretin Amyloidosis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalent Cases of hATTR

• Total Diagnosed Prevalent Cases of hATTR

• Type-specific Diagnosed Prevalent Cases of hATTR

• Stage-specific Diagnosed Prevalent Cases of FAP

• Distribution of FAC Patients by New York Heart Association (NYHA) Criteria

Download the report to understand which factors are driving Hereditary Transthyretin Amyloidosis epidemiology trends @ Hereditary Transthyretin Amyloidosis Epidemiology Forecast

Hereditary Transthyretin Amyloidosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Transthyretin Amyloidosis market or expected to get launched during the study period. The analysis covers Hereditary Transthyretin Amyloidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hereditary Transthyretin Amyloidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hereditary Transthyretin Amyloidosis Therapies and Key Companies

• Vutrisiran (AMVUTTRA): Alnylam Pharmaceuticals

• Eplontersen (WAINUA/WAINZUA): Ionis Pharmaceuticals and AstraZeneca

• Vutrisiran (AMVUTTRA): Alnylam Pharmaceuticals

• Patisiran (ONPATTRO): Alnylam Pharmaceuticals

• Inotersen (TEGSEDI): Ionis Pharmaceuticals

• Tafamidis (VYNDAMAX): Pfizer

• Nexiguran ziclumeran (nex-z): Intellia Therapeutics and Regeneron

• Nucresiran: Alnylam Pharmaceuticals

• WAINUA (eplontersen): AstraZeneca/Ionis Pharmaceuticals

• ONPATTRO (patisiran): Alnylam Pharmaceuticals

• TEGSEDI (inotersen): Ionis Pharmaceuticals

• Nexiguran Ziclumeran: Intellia Therapeutics

• ALXN2220 (formerly NI006): Neurimmune/Alexion Pharmaceuticals

• Coramitug: Novo Nordisk

• CRX-1008 (Tolcapone; SOM0226): Corino Therapeutics

• PRX004: Prothena/ Novo Nordisk

• NTLA-2001: Intellia Therapeutics/Regeneron Pharmaceutical

• Eplontersen: Ionis Pharmaceuticals/ AstraZeneca

• Acoramidis (AG 10): Eidos Therapeutics

Discover more about therapies set to grab major Hereditary Transthyretin Amyloidosis market share @ Hereditary Transthyretin Amyloidosis Treatment Market

Hereditary Transthyretin Amyloidosis Market Strengths

• The development and success of gene silencing therapies in hATTR amyloidosis is a breakthrough for adult-onset, neurodegenerative diseases.

• The upcoming therapies with their novel mechanism of action hold potential to combat the unmet need faced by the patients with hATTR-CM and hATTR-PN and provide better treatment options to the patients.

• The upcoming pipeline also includes a gene therapy based on CRISPR technology, which is currently in early phase of development. If this therapy gets approved, it could provide a cure for hATTR.

Hereditary Transthyretin Amyloidosis Market Opportunities

• The unique mechanisms of action of inotersen and patisiran overcome many limitations of previous therapies for patients with hATTR.

• Currently there is only one therapy approved for ATTR-CM in the 7MM, i.e., Vandaqel, this provides a window of opportunity for key players to develop therapies targeting ATTR-CM.

• Additional evidence for current and emerging therapies for patients with hATTR offers much‐needed hope, along with a promise of better treatment, for this debilitating and life‐threatening disease.

Scope of the Hereditary Transthyretin Amyloidosis Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Hereditary Transthyretin Amyloidosis Companies: Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia Therapeutics, Regeneron, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others

• Key Hereditary Transthyretin Amyloidosis Therapies: Vutrisiran (AMVUTTRA), Eplontersen (WAINUA/WAINZUA), Vutrisiran (AMVUTTRA), Patisiran (ONPATTRO), Inotersen (TEGSEDI), Tafamidis (VYNDAMAX), Nexiguran ziclumeran (nex-z), Nucresiran, WAINUA (eplontersen), ONPATTRO (patisiran), TEGSEDI (inotersen), Nexiguran Ziclumeran, ALXN2220 (formerly NI006), Coramitug, Eplontersen, Acoramidis (AG 10), CRX-1008 (Tolcapone; SOM0226), PRX004, NTLA-2001, and others

• Hereditary Transthyretin Amyloidosis Therapeutic Assessment: Hereditary Transthyretin Amyloidosis current marketed and Hereditary Transthyretin Amyloidosis emerging therapies

• Hereditary Transthyretin Amyloidosis Market Dynamics: Hereditary Transthyretin Amyloidosis market drivers and Hereditary Transthyretin Amyloidosis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Hereditary Transthyretin Amyloidosis Unmet Needs, KOL’s views, Analyst’s views, Hereditary Transthyretin Amyloidosis Market Access and Reimbursement

To know more about Hereditary Transthyretin Amyloidosis companies working in the treatment market, visit @ Hereditary Transthyretin Amyloidosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hereditary Transthyretin Amyloidosis Market Report Introduction

2. Executive Summary for Hereditary Transthyretin Amyloidosis

3. SWOT analysis of Hereditary Transthyretin Amyloidosis

4. Hereditary Transthyretin Amyloidosis Patient Share (%) Overview at a Glance

5. Hereditary Transthyretin Amyloidosis Market Overview at a Glance

6. Hereditary Transthyretin Amyloidosis Disease Background and Overview

7. Hereditary Transthyretin Amyloidosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Hereditary Transthyretin Amyloidosis

9. Hereditary Transthyretin Amyloidosis Current Treatment and Medical Practices

10. Hereditary Transthyretin Amyloidosis Unmet Needs

11. Hereditary Transthyretin Amyloidosis Emerging Therapies

12. Hereditary Transthyretin Amyloidosis Market Outlook

13. Country-Wise Hereditary Transthyretin Amyloidosis Market Analysis (2022–2036)

14. Hereditary Transthyretin Amyloidosis Market Access and Reimbursement of Therapies

15. Hereditary Transthyretin Amyloidosis Market Drivers

16. Hereditary Transthyretin Amyloidosis Market Barriers

17. Hereditary Transthyretin Amyloidosis Appendix

18. Hereditary Transthyretin Amyloidosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Transthyretin Amyloidosis (hATTR) Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight |Alnylam Pharma, Ionis Pharma, Novo Nordisk, AstraZeneca, Pfizer, Intellia

The Duchenne Muscular Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Duchenne Muscular Dystrophy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market

Some of the key facts of the Duchenne Muscular Dystrophy Market Report:

• The Duchenne Muscular Dystrophy market size was valued at nearly USD 4,000 million in 2025 and is expected to expand at a robust CAGR of 11% between 2026 and 2036, driven by accelerating progress in therapy development and rising demand for advanced treatment options.

• In March 2026, Sarepta Therapeutics provided an update on its ongoing regulatory interactions with the US FDA regarding VYONDYS 53 for the treatment of DMD. Sarepta requested a meeting with the FDA to discuss submitting an sNDA seeking conversion of the accelerated approval of VYONDYS 53 to traditional approvals. This request was supported by data from the ESSENCE confirmatory study; substantial, published real-world evidence supporting treatment; and the favorable safety profiles of both therapies. The Company intends to submit the sNDAs by the end of April.

• In March 2026, Regenxbio announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential best-in-class gene therapy for DMD. Trial investigator Carolina Tesi-Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children’s Health, presented this data, including new functional, safety, biomarker, and cardiac MRI measures, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.

• In January 2026, Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene-editing company leveraging its proprietary ARCUS® platform to advance in vivo gene-editing therapies for diseases with significant unmet need, announced a business update outlining its strategic priorities for 2026. The update highlighted recent advancements across its two lead programs, upcoming clinical milestones, and a solid financial position that supports execution through key value-creating inflection points.

• In January 2026, Solid Biosciences (SLDB) shares moved higher on Wednesday after the gene therapy company announced the completion of patient enrollment in its Phase 1/2 INSPIRE DUCHENNE trial evaluating its lead candidate SGT-003 in children with Duchenne muscular dystrophy, a progressive muscle-wasting disorder. The study had been planned to enroll 50–60 patients across clinical sites in the United States, Canada, Italy, and the United Kingdom.

• In January 2026, Nxera Pharma Co. Ltd (TSE: 4565) announced that it has signed an exclusive licensing agreement with Santhera Pharmaceuticals Holding (SIX: SANN) covering the development, manufacturing, and commercialization of vamorolone for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia, and New Zealand. Vamorolone is already approved and marketed under the brand name AGAMREE® for DMD, a rare inherited neuromuscular disorder, in the United States, European Union, United Kingdom, and China.

• In January 2026, Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and other areas with significant unmet medical need, announced that the FDA’s Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (DMD).

• In October 2025, Regenxbio announced the completion of enrollment in the AFFINITY DUCHENNE pivotal trial of RGX-202, an investigational gene therapy for the treatment of DMD, as well as the successful production of the first batches intended for commercial supply.

• In August 2025, The US Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to delpacibart zotadirsen (del-zota), an investigational therapy for Duchenne muscular dystrophy (DMD) in patients whose mutations are suitable for exon 44 skipping (DMD44). Developed by Avidity Biosciences, del-zota belongs to a new class of RNA-based treatments called Antibody Oligonucleotide Conjugates (AOCs™), which are engineered to enhance targeted delivery and potentially redefine therapeutic approaches for rare genetic disorders.

• In July 2025, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leading company in precision genetic medicine for rare diseases, released a statement noting that the U.S. Food and Drug Administration (FDA) informally requested the company to voluntarily pause shipments of ELEVIDYS (delandistrogene moxeparvovec), its gene therapy for Duchenne muscular dystrophy, within the U.S. Sarepta stated that it became aware of this potential request earlier in the day through media coverage, at the same time as the general public and patient communities.

• In May 2025, Satellos Bioscience’s investigational therapy SAT-3247 was found to be safe, well-tolerated, and showed early indications of improved muscle strength in five adults with Duchenne muscular dystrophy (DMD). In the initial part of the Phase 1 trial (NCT06565208), the oral small molecule, administered alongside steroids, demonstrated a favorable safety profile in healthy participants. Additionally, the drug’s pharmacokinetics—how it is absorbed, distributed, metabolized, and excreted—performed as anticipated in individuals with DMD.

• In March 2025, REGENXBIO’s investigational gene therapy, RGX-202—an adeno-associated virus (AAV) vector-based treatment for Duchenne muscular dystrophy (DMD)—continues to show promising results. Data from two additional patients in the Phase 1/2 AFFINITY DUCHENNE trial (NCT05693142) reveal that the therapy consistently generates strong levels of microdystrophin expression.

• In February 2025, Solid Biosciences reported that its gene therapy candidate, SGT-003, for Duchenne muscular dystrophy (DMD) achieved 110% microdystrophin expression in early clinical testing. The announcement of 90-day biopsy results from the Phase I/II Inspire DMD trial (NCT06138639) led to a sharp surge in the company’s stock, which rose by 78.66%—jumping from $4.03 on February 14 to $7.20 at market open on February 18. Among the first three of six enrolled patients, the observed gene expression suggests a promising potential to slow disease progression and support muscle function.

• The total number of prevalent cases of Duchenne Muscular Dystrophy in the 7MM was around 32,000 in 2025.

• The United States encompasses the highest prevalent population of Duchenne Muscular Dystrophy, around 17,500 in 2025.

• Among EU4 and the UK, the UK accounts for the highest number of prevalent cases of Duchenne Muscular Dystrophy, whereas Spain accounts for the least number of prevalent cases.

• In the US, the age group of 5-9 years accounted for the highest cases in 2025, followed by 10-14 years.

• Most cases of Duchenne Muscular Dystrophy involve non-ambulatory individuals.

• There are several comorbidities associated with Duchenne Muscular Dystrophy patients. In the United States, the maximum number of DMD patients affected with Scoliosis, followed by Attention-deficit hyperactivity disorder (ADHD) cases, was in 2025.

• Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others

• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others

• The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females

• In 2023, the age group with the highest number of cases was 5-9, totaling approximately 5,700 cases, followed by the 10-14 age group with around 5,000 cases. Duchenne muscular dystrophy (DMD) is uncommon in individuals above the age of 30.

• The Duchenne Muscular Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

Duchenne Muscular Dystrophy Overview

Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, typically becoming evident in early childhood between the ages of 3 and 5.

To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Duchenne Muscular Dystrophy Market Forecast

Duchenne Muscular Dystrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Duchenne Muscular Dystrophy Epidemiology Segmentation:

The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalent Cases of Duchenne Muscular Dystrophy

• Age-specific Cases of Duchenne Muscular Dystrophy

• Ambulatory and Non-ambulatory Cases of Duchenne Muscular Dystrophy

• Mutation-specific Cases of Duchenne Muscular Dystrophy

• Associated Comorbidities in Duchenne Muscular Dystrophy

Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Epidemiology Forecast

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Duchenne Muscular Dystrophy Therapies and Key Companies

• Deflazacort (EMFLAZA): PTC Therapeutics

• Golodirsen (VYONDYS 53): Sarepta Therapeutics

• EMFLAZA: PTC Therapeutics

• EXONDYS 51: Sarepta Therapeutics

• Pizuglanstat (TAS-205): Taiho Pharmaceutical

• RGX 202: Regenxbio

• Givinostat (ITF2357): Italfarmaco

• ATL1102: Antisense Therapeutics

• SRP-9001: Sarepta Therapeutics

• Vamorolone: Santhera Pharmaceuticals/ReveraGen Biopharma

• PF06939926: Pfizer

• Pamrevlumab: FibroGen

• CAP-1002: Capricor Therapeutics

• Pamrevlumab: Fibrogen

• Delandistrogene moxeparvovec: Roche/Sarepta Therapeutics

• EDG 5506: Edgewise Therapeutics

• WVE N531: Wave Life Sciences Ltd

• PGN EDO51: PepGen

• UX810: Ultragenyx Pharmaceutical

Discover more about therapies set to grab major Duchenne Muscular Dystrophy market share @ Duchenne Muscular Dystrophy Treatment Landscape

Duchenne Muscular Dystrophy Market Strengths

• The pipeline of DMD is robust with the advent of several potential products in late-stage of clinical development.

• Several new therapies have been approved for the treatment of DMD recently, even Japan has witnessed the launch of VILTEPSO now.

Duchenne Muscular Dystrophy Market Opportunities

• Wider commercial opportunity for therapies such as Capricor’s CAP-1002 and Antisense’s ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segment when compared to the Exon-Skipping therapies.

Scope of the Duchenne Muscular Dystrophy Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others

• Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others

• Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies

• Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Duchenne Muscular Dystrophy Unmet Needs, KOL’s views, Analyst’s views, Duchenne Muscular Dystrophy Market Access and Reimbursement

To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ Duchenne Muscular Dystrophy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Duchenne Muscular Dystrophy Market Report Introduction

2. Executive Summary for Duchenne Muscular Dystrophy

3. SWOT analysis of Duchenne Muscular Dystrophy

4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance

5. Duchenne Muscular Dystrophy Market Overview at a Glance

6. Duchenne Muscular Dystrophy Disease Background and Overview

7. Duchenne Muscular Dystrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Duchenne Muscular Dystrophy

9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices

10. Duchenne Muscular Dystrophy Unmet Needs

11. Duchenne Muscular Dystrophy Emerging Therapies

12. Duchenne Muscular Dystrophy Market Outlook

13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2022–2036)

14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies

15. Duchenne Muscular Dystrophy Market Drivers

16. Duchenne Muscular Dystrophy Market Barriers

17. Duchenne Muscular Dystrophy Appendix

18. Duchenne Muscular Dystrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Duchenne Muscular Dystrophy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | PTC Therapeutics, Sarepta Therapeutics, Taiho Pharma, Regenxbio, Fibrogen, Roche

DelveInsight’s “Brain Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Brain Cancer, historical and forecasted epidemiology as well as the Brain Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Brain Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/brain-cancer-market

Some of the key facts of the Brain Cancer Market Report:

• The Brain Cancer market size reached an estimated value of USD 2,800 million in 2025 and is anticipated to expand at a CAGR of 2.5% throughout the forecast period from 2026 to 2036.

• According to DelveInsight estimates, the United States represented the largest share of the brain cancer market in 2025, with a market size of nearly USD 1,500 million. Recent assessments further indicate potential market expansion supported by the growing adoption of innovative and targeted treatment approaches.

• In January 2026, Bayer reported ongoing evaluation of regorafenib in glioblastoma through platform trials such as GBM AGILE, highlighting its continued investigation in both newly diagnosed and recurrent settings.

• In November 2025, Northwest Biotherapeutics advanced regulatory engagement for DCVax-L following Phase III data demonstrating improved overall survival in glioblastoma patients, with efforts focused on potential approvals.

• In September 2025, Daiichi Sankyo continued post-marketing and clinical development activities for teserpaturev (DELYTACT), an oncolytic virus approved in Japan for malignant glioma, with additional studies exploring global expansion opportunities.

• In August 2025, Jazz Pharma announced US FDA approval of MODEYSO as the first and only treatment for recurrent H3 K27 M-mutant diffuse midline glioma.

• According to the estimates, the United States recorded the highest market share, i.e., around 65% of the total market size of brain cancer, in 2025.

• Among the EU4 and the UK, Germany has the maximum revenue share in 2025, while Spain has the lowest market share.

• Conditional and time-limited approval of Daiichi’s DELYTACT, an intratumoral oncolytic virus therapy, has opened new doors for other players, such as DNAtrix and Istari Oncology, to develop oncolytic virus therapies, which can prove to be a potential mechanism of action in brain cancer treatment in the future.

• According to DelveInsight’s estimates, the total incident cases of brain cancer in the 7MM were approximately 62,800 in 2025.

• It has been observed that the incidence of high-grade brain tumors is higher (~70%) than that of low-grade brain tumors (~30%) in the United States.

• It is observed that brain tumors are found to be more common in males (~58%) as compared to females (~42%) in the United States.

• Among EU4 and the UK, Germany accounted for the highest number of glioma cases, followed by France, whereas Spain had the lowest number of cases in 2025.

• In 2025, among brain tumors in other parts of the central nervous system in the United States, glioblastoma was more common in adults than in pediatrics, followed by anaplastic astrocytoma, which was also found to be more prevalent in adults than in pediatrics.

• In the United States, among all the age groups, 40–64 years accounted for the highest number of brain tumor cases, i.e., around 44%, in 2025, followed by the age group ≥65 years (39%).

• Key Brain Cancer Companies: Roche, Jazz Pharmaceuticals, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharmaceuticals, Aivita Bio-medical, Denovo Pharma, Kazia Therapeutics, Orbus Therapeutics, Eisai, Immunomic Therapeutics, Servier, Medicenna Therapeutics, NatureWise Biotech, medac GmbH, Crown Bioscience, DUSA Pharmaceuticals, Inc., Bayer, Ono Pharmaceutical Co. Ltd, NewLink Genetics Corporation, TransMolecular, Genzyme, Eli Lilly and Company, Direct Therapeutics, InSightec, Neurobiological Technologies, Monte Verde SA, Pfizer, and others

• Key Brain Cancer Therapies: Bevacizumab (AVASTIN), Dordaviprone (MODEYSO), Temozolomide (TEMODAR), Delytact, TAFINLAR (dabrafenib) + MEKINIST (trametinib), Regorafenib, LAM561 (2-OHOA), AV-GBM-1, Enzastaurin, Paxalisib (GDC-0084), Eflornithine + Lomustine, LENVIMA + KEYTRUDA, ITI-1000, Vorasidenib (AG-881), MDNA55, NBM-BMX Capsule, Gliolan, Karenitecin (BNP1350), Tumor fluorescence, Magnevist (SH L 451A), Nivolumab, Indoximod, 131I-TM-601, 89Zr-GC1008, abemaciclib, DTI-015, Doxorubicin, hCRF, Temozolomide, Palbociclib, and others

• The Brain Cancer epidemiology based on gender analyzed that Brain Tumors is slightly more common in men as compared to women

• The Brain Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Brain Cancer pipeline products will significantly revolutionize the Brain Cancer market dynamics.

Brain Cancer Overview

Brain cancer refers to the abnormal and uncontrolled growth of cells in the brain, leading to the formation of a tumor. There are various types of brain tumors, and they can be either benign (non-cancerous) or malignant (cancerous). Malignant tumors, also known as brain cancer, have the potential to invade nearby tissues and spread to other parts of the brain or the central nervous system.

To Know in detail about the Brain Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Brain Cancer Market Forecast

Brain Cancer Epidemiology

The Brain Cancer epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Brain Cancer Epidemiology Segmentation:

The Brain Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of Brain Tumor/Central Nervous System

• Total Incident Cases of Brain Cancer

• Grade-Specific Incident Cases of Brain Cancer

• Type-Specific Incident Cases of Brain Cancer

• Gender-Specific Incident Cases of Brain Cancer

• Age-Specific Incident Cases of Brain Cancer

Download the report to understand which factors are driving Brain Cancer epidemiology trends @ Brain Cancer Epidemiology Forecast

Brain Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Brain Cancer market or expected to get launched during the study period. The analysis covers Brain Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Brain Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Brain Cancer Therapies and Key Companies

• Bevacizumab (AVASTIN): Roche

• Dordaviprone (MODEYSO): Jazz Pharmaceuticals

• Temozolomide (TEMODAR): Merck

• Delytact: Daiichi Sankyo

• TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis

• Regorafenib: Bayer

• LAM561 (2-OHOA): Laminar Pharmaceuticals

• AV-GBM-1: Aivita Bio-medical

• Enzastaurin: Denovo Pharma

• Paxalisib (GDC-0084): Kazia Therapeutics

• Eflornithine + Lomustine: Orbus Therapeutics

• LENVIMA + KEYTRUDA: Eisai

• ITI-1000: Immunomic Therapeutics

• Vorasidenib (AG-881): Servier

• MDNA55: Medicenna Therapeutics

• NBM-BMX Capsule: NatureWise Biotech

• Gliolan: medac GmbH

• Karenitecin (BNP1350): Crown Bioscience

• Tumor fluorescence: DUSA Pharmaceuticals, Inc.

• Magnevist (SH L 451A): Bayer

• Nivolumab: Ono Pharmaceutical Co. Ltd

• Indoximod: NewLink Genetics Corporation

• 131I-TM-601: TransMolecular

• 89Zr-GC1008: Genzyme

• abemaciclib: Eli Lilly and Company

• DTI-015: Direct Therapeutics

• Doxorubicin: InSightec

• hCRF: Neurobiological Technologies

• Temozolomide: Monte Verde SA

• Palbociclib: Pfizer

Discover more about therapies set to grab major Brain Cancer market share @ Brain Cancer Treatment Landscape

Brain Cancer Market Strengths

• Rise in brain cancer market is attributed to several factors such as aging population, evolving research, more diagnostic tests, developing surgical approaches, improved radiotherapy techniques and novel systemic therapies.

• Various intratumoral therapies are under development which will help in overcoming the challenge of delivering the drugs across the blood-brain barrier and provide better treatment outcomes.

Brain Cancer Market Opportunities

• Due to lack of competitors in anaplastic astrocytoma, there is a substantial market opportunity for key players to develop anaplastic tumor targeting therapies.

• Numerous failed clinical trials suggest combination therapies will likely be the most promising method of GBM treatment, and emphasis should be applied to drug design and pharmacokinetic properties

Scope of the Brain Cancer Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Brain Cancer Companies: Roche, Jazz Pharmaceuticals, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharmaceuticals, Aivita Bio-medical, Denovo Pharma, Kazia Therapeutics, Orbus Therapeutics, Eisai, Immunomic Therapeutics, Servier, Medicenna Therapeutics, NatureWise Biotech, medac GmbH, Crown Bioscience, DUSA Pharmaceuticals, Inc., Bayer, Ono Pharmaceutical Co. Ltd, NewLink Genetics Corporation, TransMolecular, Genzyme, Eli Lilly and Company, Direct Therapeutics, InSightec, Neurobiological Technologies, Monte Verde SA, Pfizer, and others

• Key Brain Cancer Therapies: Bevacizumab (AVASTIN), Dordaviprone (MODEYSO), Temozolomide (TEMODAR), Delytact, TAFINLAR (dabrafenib) + MEKINIST (trametinib), Regorafenib, LAM561 (2-OHOA), AV-GBM-1, Enzastaurin, Paxalisib (GDC-0084), Eflornithine + Lomustine, LENVIMA + KEYTRUDA, ITI-1000, Vorasidenib (AG-881), MDNA55, NBM-BMX Capsule, Gliolan, Karenitecin (BNP1350), Tumor fluorescence, Magnevist (SH L 451A), Nivolumab, Indoximod, 131I-TM-601, 89Zr-GC1008, abemaciclib, DTI-015, Doxorubicin, hCRF, Temozolomide, Palbociclib, and others

• Brain Cancer Therapeutic Assessment: Brain Cancer current marketed and Brain Cancer emerging therapies

• Brain Cancer Market Dynamics: Brain Cancer market drivers and Brain Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Brain Cancer Unmet Needs, KOL’s views, Analyst’s views, Brain Cancer Market Access and Reimbursement

To know more about Brain Cancer companies working in the treatment market, visit @ Brain Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Brain Cancer Market Report Introduction

2. Executive Summary for Brain Cancer

3. SWOT analysis of Brain Cancer

4. Brain Cancer Patient Share (%) Overview at a Glance

5. Brain Cancer Market Overview at a Glance

6. Brain Cancer Disease Background and Overview

7. Brain Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Brain Cancer

9. Brain Cancer Current Treatment and Medical Practices

10. Brain Cancer Unmet Needs

11. Brain Cancer Emerging Therapies

12. Brain Cancer Market Outlook

13. Country-Wise Brain Cancer Market Analysis (2022–2036)

14. Brain Cancer Market Access and Reimbursement of Therapies

15. Brain Cancer Market Drivers

16. Brain Cancer Market Barriers

17. Brain Cancer Appendix

18. Brain Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Brain Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Roche, Jazz Pharma, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharma, Aivita Bio-medical, Denovo